Gilead To Present Investigational Compounds For Hepatitis B And Liver Fibrosis

(RTTNews) - Gilead Sciences, Inc. (GILD) announced it will present 32 scientific presentations related to its approved medicines and investigational therapies for the treatment of chronic hepatitis C virus (HCV) infection at The Liver Meeting 2015 in San Francisco. The company said the data highlighted demonstrate the strength of sofosbuvir as the backbone of multiple hepatitis C treatment regimens in numerous hepatitis C-infected patient populations.

The company will also present results from multiple studies of Viread (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis and primary sclerosing cholangitis.